TY - JOUR
T1 - Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model
AU - Tsunoda, Toshiyuki
AU - Takashima, Yasuo
AU - Fujimoto, Takahiro
AU - Koyanagi, Midori
AU - Yoshida, Yasuhiro
AU - Doi, Keiko
AU - Tanaka, Yoko
AU - Kuroki, Masahide
AU - Sasazuki, Takehiko
AU - Shirasawa, Senji
N1 - Funding Information:
Address all correspondence to: Senji Shirasawa, MD, PhD, Department of Cell Biology, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. E-mail: sshirasa@fukuoka-u.ac.jp 1This work was supported in part by the grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan. 2This article refers to supplementary materials, which are designated by Figures W1 and W2 and Tables W1 to W4 and are available online at www.neoplasia.com. 3These authors contributed equally to this work. Received 17 January 2010; Revised 15 February 2010; Accepted 16 February 2010 Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1522-8002/10/$25.00 DOI 10.1593/neo.10170
PY - 2010/5
Y1 - 2010/5
N2 - Growth and differentiation of colonic epithelium are regulated in the three-dimensional (3D) physiological architecture, colonic crypt, and deregulation of 3D interactions is involved in tumorigenesis. Cell-based 3D culture systems provide a suitable approach bridging the gap between two-dimensional (2D) culture and animal models. KRAS mutations are found at high frequencies in human colorectal cancer (CRC); however, KRAS-targeted cancer therapy has not been developed. Here, we have established a 3D cell culture model resembling the colonic crypt by use of HKe3 cells, human CRC HCT116 cells disrupted at activated KRAS. In this 3D colonic crypt model, HKe3 cells showed the features of time course-dependent transit-amplifying and terminal-differentiated stages, which are characteristic of normal colonic crypt. On the basis of the features of HCT116 cells, activated KRAS inhibited normal cell polarity and apoptosis in 3D culture. The expression of DNA repair-related tumor suppressor genes including TP53, BRCA1, BRCA2, and EXO-1 was markedly suppressed by activated KRAS in 3D culture but not in 2D culture. These results together suggest that activated KRAS plays critical roles in the accumulation of genetic alterations through inhibition of DNA repair genes and apoptosis and that this 3D culture model will provide a useful tool for investigating the molecular mechanisms of CRC development.
AB - Growth and differentiation of colonic epithelium are regulated in the three-dimensional (3D) physiological architecture, colonic crypt, and deregulation of 3D interactions is involved in tumorigenesis. Cell-based 3D culture systems provide a suitable approach bridging the gap between two-dimensional (2D) culture and animal models. KRAS mutations are found at high frequencies in human colorectal cancer (CRC); however, KRAS-targeted cancer therapy has not been developed. Here, we have established a 3D cell culture model resembling the colonic crypt by use of HKe3 cells, human CRC HCT116 cells disrupted at activated KRAS. In this 3D colonic crypt model, HKe3 cells showed the features of time course-dependent transit-amplifying and terminal-differentiated stages, which are characteristic of normal colonic crypt. On the basis of the features of HCT116 cells, activated KRAS inhibited normal cell polarity and apoptosis in 3D culture. The expression of DNA repair-related tumor suppressor genes including TP53, BRCA1, BRCA2, and EXO-1 was markedly suppressed by activated KRAS in 3D culture but not in 2D culture. These results together suggest that activated KRAS plays critical roles in the accumulation of genetic alterations through inhibition of DNA repair genes and apoptosis and that this 3D culture model will provide a useful tool for investigating the molecular mechanisms of CRC development.
UR - http://www.scopus.com/inward/record.url?scp=77951682920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951682920&partnerID=8YFLogxK
U2 - 10.1593/neo.10170
DO - 10.1593/neo.10170
M3 - Article
C2 - 20454511
AN - SCOPUS:77951682920
SN - 1522-8002
VL - 12
SP - 397
EP - 404
JO - Neoplasia
JF - Neoplasia
IS - 5
ER -